{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:13:03Z","timestamp":1792591983900,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017557","name":"SNF | Swiss National Centre of Competence in Research Kidney Control of Homeostasis","doi-asserted-by":"publisher","award":["N-403-06-26 HCP"],"award-info":[{"award-number":["N-403-06-26 HCP"]}],"id":[{"id":"10.13039\/501100017557","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Cancer League","award":["KFS-4398-02-2018"],"award-info":[{"award-number":["KFS-4398-02-2018"]}]},{"name":"Swiss Cancer League","award":["KFS-5402-08-2021"],"award-info":[{"award-number":["KFS-5402-08-2021"]}]},{"name":"Swiss National Science Fundation","award":["310030_179235"],"award-info":[{"award-number":["310030_179235"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23gm6510023"],"award-info":[{"award-number":["JP23gm6510023"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","award":["Forschungskredit UZH Postdoc 2019"],"award-info":[{"award-number":["Forschungskredit UZH Postdoc 2019"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2024,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A hallmark feature of pancreatic ductal adenocarcinoma (PDAC) is massive intratumoral fibrosis, designated as desmoplasia. Desmoplasia is characterized by the expansion of cancer-associated fibroblasts (CAFs) and a massive increase in extracellular matrix (ECM). During fibrogenesis, distinct genes become reactivated specifically in fibroblasts, e.g., the disintegrin metalloprotease,\n                    <jats:italic>ADAM12<\/jats:italic>\n                    . Previous studies have shown that immunotherapeutic ablation of ADAM12\n                    <jats:sup>+<\/jats:sup>\n                    cells reduces fibrosis in various organs. In preclinical mouse models of PDAC, we observe ADAM12 expression in CAFs as well as in tumor cells but not in healthy mouse pancreas. Therefore, we tested prophylactic and therapeutic vaccination against ADAM12 in murine PDAC and observed delayed tumor growth along with a reduction in CAFs and tumor desmoplasia. This is furthermore associated with vascular normalization and alleviated tumor hypoxia. The ADAM12 vaccine induces a redistribution of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells within the tumor and cytotoxic responses against ADAM12\n                    <jats:sup>+<\/jats:sup>\n                    cells. In summary, vaccination against the endogenous fibroblast target ADAM12 effectively depletes CAFs, reduces desmoplasia and delays the growth of murine PDACs. These results provide proof-of-principle for the development of vaccination-based immunotherapies to treat tumor desmoplasia.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00157-4","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:01:59Z","timestamp":1730293319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-2373","authenticated-orcid":false,"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sobecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Krzywinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-3124","authenticated-orcid":false,"given":"Kevin","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2426-2621","authenticated-orcid":false,"given":"M\u00e9lissa","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunmugam","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-3093","authenticated-orcid":false,"given":"Jingyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ferapontova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Seehusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-1236","authenticated-orcid":false,"given":"Dagmar","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-7908","authenticated-orcid":false,"given":"Lukas","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sexl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-1940","authenticated-orcid":false,"given":"Christian","family":"M\u00fcnz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-8559","authenticated-orcid":false,"given":"Ana","family":"Hennino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9726-6838","authenticated-orcid":false,"given":"Christian","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"issue":"3","key":"157_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/molehr\/gat084","volume":"20","author":"M Aghababaei","year":"2013","unstructured":"Aghababaei M et al (2013) A disintegrin and metalloproteinase 12 (ADAM12) localizes to invasive trophoblast, promotes cell invasion and directs column outgrowth in early placental development. Mol Hum Reprod 20(3):235\u2013249","journal-title":"Mol Hum Reprod"},{"key":"157_CR2","doi-asserted-by":"crossref","unstructured":"Airley RE et al (2003) Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104(1):85\u201391","DOI":"10.1002\/ijc.10904"},{"issue":"1","key":"157_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05220-6","volume":"9","author":"AS Cazet","year":"2018","unstructured":"Cazet AS et al (2018) Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun 9(1):2897","journal-title":"Nat Commun"},{"key":"157_CR4","doi-asserted-by":"crossref","unstructured":"Devaud C et al (2013) Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2(8):e25961","DOI":"10.4161\/onci.25961"},{"key":"157_CR5","doi-asserted-by":"crossref","unstructured":"Di Carlo SE et al (2023) Depletion of slow-cycling PDGFR\u03b1+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis. Nat Immunol 24(24):1867\u20131878","DOI":"10.1038\/s41590-023-01642-7"},{"key":"157_CR6","doi-asserted-by":"crossref","unstructured":"Dullaers M, Thielemans K (2006) From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J Gene Med 8(1):3\u201317","DOI":"10.1002\/jgm.846"},{"key":"157_CR7","doi-asserted-by":"crossref","unstructured":"Facciponte JG et al (2014) Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 124(4):1497\u20131511","DOI":"10.1172\/JCI67382"},{"issue":"7556","key":"157_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14407","volume":"522","author":"V Finisguerra","year":"2015","unstructured":"Finisguerra V et al (2015) MET is required for the recruitment of anti-tumoural neutrophils. Nature 522(7556):349\u2013353","journal-title":"Nature"},{"issue":"5","key":"157_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"key":"157_CR10","doi-asserted-by":"crossref","unstructured":"Hegde S et al (2020) Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37(3):289\u2013307","DOI":"10.1016\/j.ccell.2020.02.008"},{"key":"157_CR11","doi-asserted-by":"crossref","unstructured":"Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. npj Vaccines 4(1):1\u201310","DOI":"10.1038\/s41541-019-0103-y"},{"key":"157_CR12","doi-asserted-by":"crossref","unstructured":"Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582\u2013598","DOI":"10.1038\/nrc.2016.73"},{"key":"157_CR13","doi-asserted-by":"crossref","unstructured":"Krzywinska E et al (2017) Loss of HIF-1\u03b1 in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun 8(1):1597","DOI":"10.1038\/s41467-017-01599-w"},{"issue":"1","key":"157_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajpath.2018.09.009","volume":"189","author":"KJ Lafaro","year":"2019","unstructured":"Lafaro KJ, Melstrom LG (2019) The paradoxical web of pancreatic cancer tumor microenvironment. Am J Pathol 189(1):44\u201357","journal-title":"Am J Pathol"},{"key":"157_CR15","doi-asserted-by":"crossref","unstructured":"Lynch MD, Watt FM (2018) Fibroblast heterogeneity: implications for human disease. J Clin Invest 128(1):26\u201335","DOI":"10.1172\/JCI93555"},{"issue":"5933","key":"157_CR16","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP et al (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457","journal-title":"Science"},{"issue":"6","key":"157_CR17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719\u2013734","journal-title":"Cancer Cell"},{"issue":"11","key":"157_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.trecan.2019.09.010","volume":"5","author":"BA Pereira","year":"2019","unstructured":"Pereira BA et al (2019) CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer 5(11):724\u2013741","journal-title":"Trends Cancer"},{"key":"157_CR19","doi-asserted-by":"crossref","unstructured":"Pincha M, Sundarasetty BS, Stripecke R (2010) Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 9(3):309\u2013321","DOI":"10.1586\/erv.10.9"},{"issue":"1","key":"157_CR20","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"157_CR21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.stem.2022.08.012","volume":"29","author":"M Sobecki","year":"2022","unstructured":"Sobecki M et al (2022) Vaccination-based immunotherapy to target profibrotic cells in liver and lung. Cell Stem Cell 29(10):1459\u20131474.e9","journal-title":"Cell Stem Cell"},{"key":"157_CR22","doi-asserted-by":"crossref","unstructured":"Stripecke R (2009) Lentiviral vector-mediated genetic programming of mouse and human dendritic cells. Methods Mol Biol 506:139\u2013158.","DOI":"10.1007\/978-1-59745-409-4_11"},{"key":"157_CR23","doi-asserted-by":"crossref","unstructured":"Thomas D, Radhakrishnan P (2019) Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer 18(1):14","DOI":"10.1186\/s12943-018-0927-5"},{"key":"157_CR24","doi-asserted-by":"crossref","unstructured":"Uhlig KM et al (2015) Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response. J Virol 89(17):9044\u20139060","DOI":"10.1128\/JVI.00844-15"},{"key":"157_CR25","doi-asserted-by":"crossref","unstructured":"Veenstra VL et al (2018) ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 7(11):87","DOI":"10.1038\/s41389-018-0096-9"},{"issue":"1","key":"157_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10968-6","volume":"10","author":"C Vennin","year":"2019","unstructured":"Vennin C et al (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat Commun 10(1):3637","journal-title":"Nat Commun"},{"key":"157_CR28","doi-asserted-by":"crossref","unstructured":"Yang X, Jones K, Chen G (2021) Pathology of Pancreatic Ductal Adenocarcinoma. Magy Onkol 65:1\u201335.","DOI":"10.1007\/978-3-030-37482-2_30-1"},{"key":"157_CR27","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhu L, Wang X (2020) A network-based approach for identification of subtype-specific master regulators in pancreatic ductal adenocarcinoma. Genes 11(2):155","DOI":"10.3390\/genes11020155"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00157-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00157-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:46:46Z","timestamp":1786034806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00157-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,9]]}},"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00157-4","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application based on this work has been deposited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"3"}}